BioEmu, a groundbreaking model, revolutionizes protein structure prediction by sampling from the equilibrium distribution of structures for a protein monomer based on its amino acid sequence, providing inference code, model weights, and availability as a Linux package and on Azure AI Foundry.
In a major shakeup, Windsurf's CEO, co-founder, and top researchers defect to Google DeepMind after OpenAI's $3 billion acquisition falls through, with Google paying $2.4 billion to license Windsurf's technology and hire its key personnel.
Mark Zuckerberg spearheads Meta's pursuit of superintelligence, aggressively recruiting elite AI talent with lucrative offers and constructing massive GPU clusters dubbed 'Tents' to exponentially scale training capabilities.
Elon Musk's AI company xAI launches Grok 4, its latest flagship AI model boasting frontier performance, alongside a $300 monthly SuperGrok Heavy subscription for early premium access.
Elon Musk's xAI unveils Grok-4, a groundbreaking AI model shattering benchmarks across disciplines with near-perfect scores on graduate-level tests and unseen problem-solving, doubling the accuracy of its closest competitor.
Grok 4, a groundbreaking multimodal AI, unveils deeper thinking, faster performance, and multimodal capabilities supporting text, images, and potentially video, aiming to overcome bias concerns with improved content moderation for enhanced credibility.
In a major AI talent move, Apple's AI chief Ruoming Pang, responsible for developing language models and features, departs for Meta's newly formed Superintelligence Labs, as the tech giants compete for top AI talent.
OpenAI intensifies the war for AI talent, poaching 4 high-ranking engineers from Tesla, xAI, and Meta to bolster its scaling team and build advanced AI infrastructure.
Meta strikes a blow in the AI talent war, poaching Ruoming Pang, Apple's head of AI models who oversaw training for the tech giant's in-house AI systems, in a potential exodus from Apple's troubled artificial intelligence division.
AI startup Isomorphic Labs, spun out of DeepMind, prepares for human trials of drugs designed by cutting-edge AI paired with pharma experts, aiming for 100% conviction drugs will work before trials, promising faster, cheaper and more accurate medicine design.